Aims Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis
(ST) and bleeding, standardized and clinically validated thresholds for accurate risk …

The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …

Point-of-care (POC) assays are available for a variety of coagulation tests. These assays are
generally simple to perform and have a more rapid turnaround time than their central …

Context High on-treatment platelet reactivity is associated with atherothrombotic events
following coronary stent implantation. Objective To evaluate the capability of multiple platelet …

Coronary artery stents revolutionized the practice of interventional cardiology after they were
first introduced in the mid-1980s. Since then, there have been significant developments in …

Objectives: The purpose of the study was to systematically evaluate the significance of
platelet reactivity on clopidogrel treatment on adverse cardiovascular events using a …

Background—In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on
Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce …

Objectives: The aim of this prospective trial was to assess whether platelet reactivity to
clopidogrel assessed with multiple electrode platelet aggregometry (MEA) correlates with …

Related US Application Data 2 () 13/() 19 () 265 A 1 7/20 13 Arculus-Meanwell et al. 2 ()
13/() 3 () 3477 A 1 1 1/2 () 13 (Chen et g1,(63) Continuation of application No. 14/269,429 …